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Among brain tumors, glioblastoma multiforme appears as one of the most
aggressive forms of cancer with poor prognosis and no curative treatment
available. Recently, a new kind of radio-chemotherapy has been developed
using synchrotron irradiation for the photoactivation of molecules with high-Z
elements such as cisplatin (PAT-Plat). This protocol showed a cure of 33% of
rats bearing the F98 glioma but the efﬁciency of the treatment was only
measured in terms of overall survival. Here, characterization of the effects of the
PAT-Plat on tumor volume and tumor blood perfusion are proposed. Changes
in these parameters may predict the overall survival. Firstly, changes in tumor
growth of the F98 glioma implanted in the hindlimb of nude mice after the PAT-
Plat treatment and its different modalities have been characterized. Secondly,
the effects of the treatment on tumor blood perfusion have been observed by
intravital two-photon microscopy. Cisplatin alone had no detectable effect on
the tumor volume. A reduction of tumor growth was measured after a 15 Gy
synchrotron irradiation, but the whole therapy (15 Gy irradiation + cisplatin)
showed the largest decrease in tumor growth, indicating a synergistic effect
of both synchrotron irradiation and cisplatin treatment. A high number of
unperfused vessels (52%) were observed in the peritumoral area in comparison
with untreated controls. In the PAT-Plat protocol the transient tumor growth
reduction may be due to synergistic interactions of tumor-cell-killing effects and
reduction of the tumor blood perfusion.
Keywords: synchrotron photoactivation therapy; cisplatin; glioma; two-photon microscopy;
synergistic effects.
1. Introduction
Radiotherapy has increased the overall survival of patients
with primary brain tumors; however, the dose is limited by the
radiosensitivity of the surrounding tissues (Schultheiss et al.,
1995). A total dose of 60 Gy, delivered in 30 fractions of 2 Gy,
is the maximum dose recommended for the treatment of
glioblastoma multiforme. This dose is too low to sterilize the
tumor that inevitably recurs.
Chemotherapy effects are generally poor as the drug
delivery to the tumor is difﬁcult (Muldoon et al., 2007). The
blood-brain barrier (BBB), despite its disruption in some part
of the tumor, and the interstitial ﬂuid pressure are the main
obstacles to the free diffusion of therapeutic molecules.
Moreover, tumor cells often migrate in healthy surrounding
tissues at the distance of the original lesion where the BBB is
still intact. In spite of the drawbacks of radiotherapy and
chemotherapy, a combination of both have improved the
survival of patients (Bartelink et al., 2002; Stupp et al., 2005).
Another approach to ameliorate the percentage of survi-
vors may be to increase the local dose deposition during
radiotherapy using X-ray photoactivatable drugs. This chemo-
radiotherapy was successfully tested at the European
Synchrotron Radiation Facility (ESRF) (Biston et al., 2004;
Adam et al., 2003). This method, synchrotron stereotactic
radiotherapy, consists of a tomographic irradiation of the
tumor volume with kilo-voltage synchrotron X-rays after
loading the tumor with high-Z compounds such as iodine
(Adam et al., 2003, 2006) or platinum (Biston et al., 2004). An
irradiation of a high-Z compound around its K-edge results
merely in a photoelectric effect generating photoelectrons.
Cisplatin [cis-diamminedichloroplatinum(II)] is a chemother-
apeuthic drug that is used in the treatment of solid tumors
and forms adducts with DNA (Boulikas & Vougiouka, 2003).
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Biston et al. (2004) demonstrated that rats
bearing F98 gliomas were cured after the
intratumoral injection of cisplatin followed
24 h later by synchrotron irradiation. In that
study, survival analyses were performed,
whereas the aim in the present study is to
understand and to analyse underlying tumor
morphological and physiological changes that
determine survival, such as volume and blood
perfusion at the presence and absence of the
photoelectric effects. Changes in these para-
meters were measured in time after different
treatment modalities on F98 gliomas growing
in the hindlimb of nude mice. This hetero-
topic glioma model was preferred over an
orthotopic glioma model, because tumor
volume changes can be easily evaluated and intravital two-
photon microscopy observations (Helmchen & Denk, 2005;
Denk et al., 1990) of modiﬁcations in tumor blood perfusion in
peritumoral areas can be accomplished.
2. Materials and methods
2.1. Animal care guidelines
In accordance with the policy of Grenoble Institute of
Neuroscience and the French legislation, experiments were
performed in compliance with the European Community
Council Directive of 24 November 1986 (86/609/EEC). The
research on animals was authorized by the Direction De´par-
tementale des Services Ve´te´rinaires de l’Ise`re, Ministe`re de
l’Agriculture et de la Peˆche, France and the Direction
De´partementale de la protection des populations, Pre´fecture
de l’Ise`re-France (B. van der Sanden, PhD, permit number
38 09 40). Five-week-old female nude mice (n = 146; Charles
River Laboratories, France) were housed in cages with food
and water ad libitum in a 12 h light/dark cycle at 295  1 K.
2.2. Tumor implantation
Animals were brieﬂy anesthetized with inhalation of
isoﬂurane (4%) in air. 50 ml of a solution of 105 F98 glioma
cells in DMEM was slowly injected subcutaneously in the left
hindlimb of the animal. Animals were housed under standard
conditions for 2.5 weeks or 3.5 weeks in order to obtain tumors
with a mean volume of 106  11 mm3 (small-volume group)
and 480 33 mm3 (large-volume group), respectively. The F98
glioma model is highly proliferative and has the characteristics
of a high-grade glioma (Mathieu et al., 2007).
For the small tumor groups (Table 1), 18 mice were injected
with eGFP expressing F98 glioma cells. These cells were stably
transfected with a plasmid expressing eGFP under the control
of the CMV promoter (peGFP-N1 vector; Clontech Labora-
tories, Palo Alto, CA, USA).
2.3. Irradiation procedure
2.3.1. Animal preparation. Animals were randomized into
eight different groups (see Table 1). Twenty-four hours before
the irradiation, 2.5 mg of cisplatin (Cisplatyl, Sanoﬁ-Aventis,
Paris, France) in 50 ml of a saline solution was injected
manually into the center of the tumor with a 29 gauge needle
for 30 s. In the study of Biston et al. (2004), the cisplatin
distribution was homogeneous in the tumor 24 h after intra-
tumoral injection as measured by X-ray ﬂuorescence. The
following day, animals were anaesthetized with an intraper-
itoneal injection of a mixture of 10 mg kg1 xylazine and
100 mg kg1 ketamine in a 0.9% NaCl saline solution. They
were positioned on a home-made horizontal frame with the
left hindlimb immobilized vertically in a plexiglass tube
(Fig. 1). Their body temperature was maintained at physio-
logical conditions during the whole experiment using heated
gels.
2.3.2. ESRF source. A highly collimated and monochromatic
synchrotron beam was used. The radiation source was a multi-
magnet wiggler situated 150 m upstream of the animal.
Divergence of the source was 0.1 mrad vertically and about
3 mrad horizontally. Collimation slits were set to deﬁne a fan
beam of 1.5 mm  40 mm. The beam was monochromated at
79 keV, just above the absorption K-edge of the platinum
(78.39 keV). Monochromatization was achieved by means of
a pair of bent silicon crystals in transmission (Laue) mode.
Band-pass was approximately 80 eV.
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Table 1
Animals (n = 146) were randomized in eight groups depending on their tumor volume at the
beginning of the therapy and the type of treatment.
Experiment Group Type of treatment Number of mice
Large volume
(mean tumor
volume: 480 mm3)
1 Control 14
2 2.5 mg Cisplatin 7
3 Irradiation 13
4 Whole treatment 27
Small volume
(mean tumor
volume: 106 mm3)
5 Control 6 + 6 implanted with F98-GFP cells
6 2.5 mg Cisplatin 7 + 3 implanted with F98-GFP cells
7 Irradiation 5 + 3 implanted with F98-GFP cells
8 Whole treatment 18 + 6 implanted with F98-GFP cells
5 mg Cisplatin (Control, 5 mg cisplatin,
irradiation, whole
treatment)
31
Figure 1
Irradiation set-up. Schematic representation of the positioning of the
mouse in the horizontal frame with the left hindlimb maintained in a
vertical plexiglas tube.
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The animals on the horizontal frame (see Fig. 1) were ﬁxed
on a rotation and translation motorized stage. The rotation
axis was positioned in the middle of the tube so that with a
1.5 mm-high and 40 mm-wide beam the whole surface within
the cylinder (diameter = 20 mm) was irradiated. Before each
irradiation, radiography of the left hindlimb of the mouse was
performed. The radiography helped to localize the tumor and
to determine the area to be irradiated. Animals were irra-
diated in multiple slices 1.5 mm high while rotating in a
tomographic mode in order to have a more homogeneous dose
deposition in the tissues; the total height of the irradiated
volume varied between 12 and 21 mm (eight to 14 joining
slices of height 1.5 mm) depending on the size of the tumor.
The dose rate was 9.896  104 Gy mA1 s1 as measured at
the skin entrance inside the plexiglas tube (Fig. 1), normalized
to the electron current of the synchrotron storage ring. The
device rotation speed was adjusted to deliver 15 Gy to the
center of rotation. This dose was chosen as it has proven to
have the best effects on rats bearing F98 gliomas (Biston et al.,
2004; Rousseau et al., 2007a).
2.4. Tumor volume measurements
The reference tumor volume of all animals in the different
groups (t = 0) was measured 24 h before the irradiation
whether the group was irradiated or not. After the irradiation,
the tumor growth was regularly evaluated. Length l and width
w of the tumor were measured using a caliper. The height of
the tumor was not taken into account. This may overestimate
tumor volume in groups 4 and 8, where in 15% of the cases a
central collapse was observed. The volume V was calculated
using the following equation: V = (4/3)lw2. The reference
tumor volume was normalized to 100 in every graph of this
paper. Statistical analyses were realised using GraphPad
Prism4 software (San Diego, USA). A Student’s unpaired
two-tailed t test was used to compare the mean values. Data
are presented as mean  SEM (standard error of the mean)
and differences between the means were considered to be
statistically signiﬁcant at a probability of p < 0.05.
2.5. Two-photon microscopy
2.5.1. Animal preparation. Five days after the irradiation,
mice were anesthetized with a continuous inhalation of
isoﬂurane (2%) in a gas mixture of O2 and N2O (30% and
70%, respectively). The hindlimb of the mouse was blocked in
a home-made restrain in order to reduce the breathing
movements. Core temperature was maintained at approxi-
mately 310 Kusing warm water circulating through a pad. Skin
(4–5 mm in diameter) was removed above the tumor. An
image of the exposed area was recorded using a Pentax IstDL
camera mounted on a macroscope (Leica MZ6).
Two different experiments were performed:
(i) Estimation of the percentage of the non-perfused vascular
surface area after PAT-Plat. In F98 gliomas of the control
group 1 and the whole treatment group 4, a cocktail of 100 ml
of a 100 mg ml1 FITC-dextran 70 kDa solution (Sigma-
Aldrich) and 50 ml of a 10 mg ml1 0.56 kDa sulforhodamineB
(SRB) solution (Lambda Physics) in 0.9% NaCl was injected
into the tail vein. The freely diffusible SRB stained the extra-
vascular volume and the perfused vessels of the tumor except
the non-perfused vessels [see Figs. 2(e) and 2( f)].
(ii) Analysis of tumor cell morphology and tumor blood
perfusion changes for all treatment modalities. In F98-GFP
gliomas (groups 5–8), the perfused vasculature was stained
with 100 ml of a 100 mg ml1 rhodamineB-dextran 70 kDa
solution (Sigma-Aldrich). The numbers of GFP-F98
implanted animals are indicated in Table 1.
2.5.2. Microscopy set-up. Two-photon laser-scanning
microscopy was performed with a Biorad MRC 1024 scanhead
and an Olympus BX50WI microscope. Fluorescence signal
was directly epicollected. An 800 nm excitation beam from a
Tsunami femtosecond Ti:sapphire laser (5 W pump; Spectra-
Physics, Millenia V) was focused onto the surface of the tumor
using a 20 water-immersion objective (0.95 NA, Xlum Plan
Fl Olympus). The beam was scanned in the xy plane to acquire
512 512 pixel images in 0.9 s between 0 to 200 mm below the
surface. Variation of the observation depth (z-scan) was
realised by moving the motorized objective vertically. The
incident laser intensity was adjusted by using a half-wave plate
and a polarizer placed before the microscope. Total average
power delivered at the surface ranged from 1 to 150 mW. Two
channels (red and green) could be simultaneously observed
using two added external photomultiplier tubes (PMTs)
equipped with an appropriate set of ﬁlters: HQ 620/60 and 710
ASP in front of PMT1 (red channel); HQ 535/30 and BG39 in
front of PMT2 (green channel). Images were acquired using
the Biorad exploitation system and displayed using ImageJ
software (version 1.36, Public Domain Software, available
from http://rsb.info.nih.gov/ij/).
2.5.3. Measurement of the non-perfused vascular surface.
Quantiﬁcation of the non-perfused vascular surface per
surface of the whole tumor sections in the two-photon image
was assessed on the merged image showing the perfused
vessels (FITC-dextran, green) and the extravascular space
after diffusion of SRB (red) (Fig. 2f). Two-photon images
were analyzed at a depth of 50 mm beneath the surface of the
tumors. Note that only perfused tumor vessels were presented
at the tumor periphery in the control group until a depth of
maximum 100 mm (see Fig. 2c). Note that in Figs. 2(e) and 2( f)
we used FITC-dextran (green signal) instead of rhodamineB-
dextran (red signal) to stain the functional vessels, because the
freely diffusible red dye SRB was applied to stain the whole
extravascular space.
After selection of the whole tumor surface area, in two-
photon images like in Fig. 2( f) the merged color image was
binarized and the percentage of the non-perfused black pixels
was calculated as follows: [(all tumor surface area pixels 
white pixels)/all tumor surface area pixels]  100. The white
pixels are the pixels that contained a ﬂuorescence signal:
whether FITC-dextran (green) in perfused vessels or SRB
(red) in the extravascular space (see Fig. 2f). After intra-
venous injection of both dyes, the SRB diffused freely from
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functional tumor vessels inside the extravascular space of the
tumor, but did not stain the lumen of non-perfused vessels that
remained dark.
These calculations were performed for four mice at day 5
after the whole PAT treatment (group 4, Table 1) and for six
control mice (group 1, Table 1). Data are presented as mean
standard deviation.
2.6. Immunohistochemistry
2.6.1. Slice preparation. Animals (control groups 1 and 5,
n = 6) were sacriﬁced and their left hindlimbs were excised and
frozen in isopentane at 193 K. Slices of thickness 10 mm were
cut on a cryotome (Microm HM560) and conserved at 251 K
until the histological and immunohistochemistry experiments.
2.6.2. Immunohistochemistry. For the staining of the basal
lamina of all tumor vessels, sections were ﬁxed in a solution of
paraformaldehyde (4%) and then permeabilized with a lysis
buffer: sucrose 300 mM, MgCl2 3 mM, Tris 20 mM, NaCl
50 mM and Triton 0.5%. They were incubated overnight at
277 K with goat anti-collagen IV (1/100, Southern Biotech) in
PBS-BSA 3%. Finally, sections were incubated during 90 min
at room temperature with FITC conjugated donkey anti-goat
(1/100, Jackson Immunoresearch) in PBS-BSA 3%. Slices
were mounted with a mounting medium (Biomeda, Foster
City) containing Hoechst 33342 (2 mg ml1) for the staining of
all nuclei and observed on a Nikon epiﬂuorescence micro-
scope (type Eclipse E600) connected to a digital color camera
(Olympus, Color View II) and analySIS software (Version 5,
Soft Imaging System, Olympus, Munster, Germany) for image
acquisition and processing.
3. Results
The effects of the different treatment modalities were
analyzed, regarding tumor volume, tumor blood perfusion and
glioma cell morphology on large and small tumor groups
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Figure 2
Effects of the treatment on tumor vasculature. (a) Macrophotography of the surface of the F98 glioma implanted in the hindlimb of a mouse after the
removal of the skin. (b) Immunohistochemistry performed on a section in the middle of a F98 glioma. Green: immunolabelling of the collagen IV
indicating the basal lamina of the vasculature in the peritumoral area; blue: cell nuclei stained with Hoechst 33342. Note the necrotic core at the center of
the tumor. (c) Two-photon imaging of an untreated F98-GFP glioma at day 5 after the beginning of the study. Green: GFP-F98 glioma cells; red:
rhodamineB-dextran 70 kDa dye staining of blood vessels. Only the tumor periphery is perfused until a maximum depth of approximately 100 mm. All
two-photon images, (c)–( f ), were taken at a depth of 50 mm beneath the surface of the tumor. (d) Two-photon imaging of a F98-GFP glioma at day 5
after receiving 15 Gy 79 keV tomographic synchrotron irradiation. Green: GFP-F98 glioma cells; red: rhodamineB-dextran 70 kDa dye staining the
blood vessels. The tumor periphery is still perfused. The solid tumor mass decreased; see the empty space between functional red vessels and the green
tumor cells. In comparison with the control tumors (c), cell morphology has changed from elongated shapes into round shapes. (e) Two-photon imaging
of an untreated F98 glioma at day 5 after the beginning of the study. Green: vasculature labeled by FITC-dextran 70 kDa; red: sulforhodamineB dye
extravascated in the extravascular extracellular tumor volume in order to obtain a better contrast. A rolling-ball background subtraction with a radius of
ten pixels was applied (with this method, a local background value is determined for every pixel by averaging over a very large ball around the pixel; this
value is then subtracted from the original image, removing variations of the background intensities). Note that for the staining of the functional vessels,
FITC-dextran (green signal) instead of rhodaminB-dextran (red signal) is used. ( f ) Two-photon imaging of a F98 glioma at day 5 after the whole
treatment. Note that the non-perfused vessels areas appear dark (see white arrows) and a few functional vessels show up green after perfusion with
FITC-dextran surrounded by a red SRB staining of the whole extravascular volume. A rolling-ball background subtraction with a radius of ten pixels was
applied. (g) Unperfused vascular surface (%) in control (group 1) and PAT-Plat (group 4) animals at ﬁve days post-treatment. (h) Tumor growth in
control (group 1; red squares) and PAT-Plat (group 4; green diamonds) animals during the ﬁrst three weeks post-treatment. The decrease of the perfused
vascular surface observed in PAT-Plat animals (g) can be correlated with the reduction of the tumor growth.
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within 40 days after the start of a treatment. The rationale
behind this choice was to study the consequences of the
treatment at two different stages of glioma progression.
3.1. Treatment of large tumor volumes
Experiments were ﬁrst conducted on tumors with a mean
volume of 480  33 mm3 at the start of the treatment. Intra-
tumoral injection of cisplatin elicited no modiﬁcations of the
tumor growth neither with 2.5 mg (Fig. 3a) nor with 5 mg
(results not shown). A synchrotron irradiation with a dose of
15 Gy and energy of 79 keV induced a decrease of the growth
rate observable as early as one week after the irradiation
(Fig. 3a). More interestingly, the whole treatment (cisplatin +
irradiation) led to a higher decrease of the growth rate in
comparison with irradiation alone. The difference between
irradiation alone and the whole treatment is signiﬁcant
starting at three weeks after the irradiation (Fig. 3a). It must
be noted that the volume decrease after the whole treatment is
enhanced with an injection of 5 mg of cisplatin rather than with
2.5 mg (results not shown). However, systemic toxicity of the
whole PAT-Plat protocol with a 5 mg injection of cisplatin was
observed as all animals died approximately at 28 days post-
irradiation. These systemic toxicity effects were not observed
in the other groups of Table 1.
3.2. Treatment of small tumor volumes
The same experiments were performed on tumors with a
mean volume of 106  11 mm3. A dose of 2.5 mg of cisplatin
per tumor was used to avoid systemic toxicity effects as seen at
a dose of 5 mg per tumor. The efﬁciency of the whole treat-
ment (group 8) in comparison with irradiation only (group 7)
was signiﬁcant, starting from two weeks after irradiation
(Fig. 3b). This is one week earlier than observed for the large
tumors. Moreover, the difference between these two groups
remains signiﬁcant at longer delays (42 days), which is not
found in the large tumor group. Finally, cisplatin treatment
alone still had no signiﬁcant effects on the tumor volume
(Fig. 3b).
3.3. Effects on the tumor vasculature and cell morphology
We have investigated the effects of the whole PAT-Plat
treatment and its different modalities on tumoral vasculature
to see whether the effects observed on tumor volume were
possibly related to earlier modiﬁcations of the tumor blood
perfusion.
Non-treated F98 glioma exhibit a necrotic core surrounded
by a proliferative peritumoral area that is highly vascularized.
Angiogenic vessels that were found in these areas are large
and disorganized [Figs. 2(a) and 2(b)–2(e)]. At ﬁve days after
irradiation, in gliomas of group 7 (irradiation only, Fig. 2d), we
observed a reduction of GFP-positive glioma cells at the
periphery and a change in their cell shapes in comparison with
the control group 5 (Fig. 2c). They showed more round-shapes
in comparison with elongated-shapes in the control group.
Note that the vasculature at the tumor periphery [Fig. 2(d),
red rhodamineB-dextran staining] was still perfused after
irradiation, in comparison with gliomas of group 4 [Fig. 2( f),
green FITC-dextran staining].
Five days after the whole treatment, many vessels were not
perfused [see arrows in Fig. 2( f)] in comparison with
untreated controls (Fig. 2e). The percentage of the unperfused
vascular surface was 5 5% in controls (group 1, Table 1) and
52  5% in PAT-treated animals (group 4, Table 1) (Fig. 2g).
The percentage of the unperfused vascular surface could not
be estimated for the small tumor groups 5 and 8, because red
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Figure 3
(a) Effects of the therapy on tumor growth for animals bearing a large
tumor (mean volume 480  33 mm3) at the moment of the treatment.
Effects of the intratumoral injection of 2.5 mg of cisplatin alone (group 2;
black down-triangles), the radiotherapy alone (group 3; blue up-
triangles), the whole treatment with 2.5 mg of cisplatin (group 4; green
diamonds) and no treatment (group 1; red squares) on the tumor growth.
(b) Effects of the therapy on tumor growth for animals bearing a small
tumor (mean volume 106  11 mm3) at the moment of the treatment.
Effects of the intratumoral injection of 2.5 mg of cisplatin alone (group 6;
black down-triangles), the radiotherapy alone (group 7; blue up-
triangles), the whole treatment with 2.5 mg of cisplatin (group 8; green
diamonds) and no treatment (group 5; red squares) on the tumor growth.
For each group the tumor volume was normalized to 100 at the moment
of the treatment. &: p < 0.05 whole treatment versus control; #: p < 0.05
irradiation alone versus control; +: p < 0.05 whole treatment versus
cisplatin alone; £: p < 0.05 irradiation alone versus cisplatin alone; $: p <
0.05 whole treatment versus irradiation alone; : p < 0.05 cisplatin alone
versus control; unpaired two-tailed Student’s t-test.
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rhodamineB-dextran signals in the perfused vessels could not
be separated from the intense red background in the two-
photon images (see Fig. 2d). All these changes in tumor blood
perfusion and cell shapes were observed before a decrease in
tumor volume (Figs. 3 and 2h). Tumor blood perfusion
changes were only observed after the PAT protocol in group 4.
4. Discussion
Up to now, effects of the PAT-Plat on the F98 glioma were
essentially observed in terms of animal survival (Biston et al.,
2004; Rousseau et al., 2007a). In the present study, the effects
of the PAT-Plat on the functional tumor vasculature followed
by tumor volume changes were analyzed in time. For this
purpose, a nude mouse model with F98 gliomas (Mathieu et
al., 2007) implanted in the hindlimb was used. This allowed
longitudinal observations of the tumor volume without using
imaging techniques such as magnetic resonance imaging.
Moreover, it enables the observation of the vasculature in the
peritumoral area (Bergers & Benjamin, 2003; Jain et al., 2007)
using intravital two-photon microscopy. Finally, in the glioma
nude mouse model, the effect of T-cell mediated immune
response can be avoided in the treatment response. We have
chosen to test the chemo-radiotherapy treatment on two
tumor groups with different volumes at the start of the
treatment. The rationale behind this choice is to have an early
stage of glioma development and a mature stage with a
necrotic core.
Combination of chemotherapy using halogenated agents
such as cisplatin and radiotherapy has shown to improve the
prognosis of a large array of malignancies including head and
neck, lung and cervical cancer (Bartelink et al., 2002). Drug
delivery was also considered as a major concern. Systemic i.v.
infusion of the chemotherapeutic agent is often the source of
important side effects (Muldoon et al., 2007; Marshall et al.,
2006; Nakagawa et al., 1993; Boulikas & Vougiouka, 2003) and
poor drug accumulation in the tumor core. In our protocol,
cisplatin was injected directly into the tumor 24 h before the
irradiation in order to maximize the drug concentration in the
tumor volume. In the study of Biston et al. (2004) the cisplatin
distribution was homogeneous in the tumor 24 h after intra-
tumoral injection as measured with X-ray ﬂuorescence. We
based our onset of irradiation on these observations. This time
is long enough for diffusion inside the cells and cross-linking
with DNA. At 24 h after cisplatin injection, we probably
exclude free unbound cisplatin in the tumor.
Another method, convection enhanced delivery, may
provide a better control of the injection and drug distribution
in the tumor (Rousseau et al., 2007b).
In the following section, the effects of the therapy in terms
of tumor volume and vascular modiﬁcations are discussed and
a possible link between these two parameters is suggested.
4.1. Effects of the treatment on tumor growth
4.1.1. Effect of radiation only. In the present paper, it was
observed that a 15 Gy/79 keV irradiation decreased the tumor
growth rate. Biston et al. (2004) and Adam et al. (2006) have
both reported a median survival time of 26 days for rats
implanted with 1000 F98 cells in the striatum. The median
survival time was extended to 48 days and 46 days, respec-
tively, after a 15 Gy irradiation. In our study, the tumor growth
decrease was observed for three weeks following the irradia-
tion, followed by an exponential increase. This decrease in
tumor growth observed for three weeks (21 days) following
the treatment is close to the increase survival observed by
Biston et al. (2004) and Adam et al. (2003): 22 and 20 days,
respectively.
Bencokova et al. (2007) classiﬁed F98 glioma cells as a
moderate radiosensitivity cell line. They quantiﬁed the cell
surviving fraction in vitro at 2 Gy to be 41.4  2.5%. Despite
this moderate radiosensitivity, the irradiation did not seem to
sterilize the tumor cells (Fig. 2d). In this ﬁgure we showed that
a large amount of F98 glioma cells (GFP+) died but the whole
tumoral volume was not sterilized. Recurrence occurred three
weeks after the irradiation.
4.1.2. Effects of the PAT-Plat. After PAT-Plat, the tumor
growth rate decrease was more important than after irradia-
tion only. For the animals bearing a large-volume tumor at the
moment of the treatment, regardless of the dose of cisplatin
injected (2.5 or 5 mg), the difference between the irradiated
group and the whole treatment group is signiﬁcant starting
from three weeks after the irradiation. For animals bearing a
small-volume tumor at the moment of the treatment, this
difference is signiﬁcant starting from two weeks after the
irradiation. However, animals were not cured.
These results differ from those of Biston et al. (2004), who
have shown 33% cure of rats after the complete PAT-Plat
therapy. The discrepancy can in part be explained by the role
of the T-cell mediated immune response, which is present in
the Fisher rat model but absent in the nude mouse model. The
stimulation of the immune response after radiotherapy may
partly account for tumor ablation. The immune system can
have a central role in the response to tumor aggression. We
hypothesize that the absence of animals showing a whole
remission in this study can be accounted for by the absence of
immune response.
We have observed that the reduction of the growth rate was
more important for a 5 mg dose of cisplatin. However, the
toxicity of the treatment under these conditions is high and,
despite a stabilization of the growth curve, all animals died
at day 28 post-treatment. Surprisingly, irradiation or 5 mg
cisplatin alone did not induce an early death. We hypothesize
that irradiation of cisplatin may produce radiolysis by-
products of the latter, which may increase the systemic toxicity
at higher concentrations of cisplatin and possibly participate in
the synergetic effects of PAT (Gastaldo et al., 2011).
In PAT-Plat studies on F98 glioma bearing rats (Biston et al.,
2004; Rousseau et al., 2007a) with a normal immune response,
a distinction between additive or synergistic effects could not
be made. In the present study, observations made on the
various groups of animals have shown that cisplatin has no
signiﬁcant effects on the tumor growth; irradiation decelerates
it and the whole treatment induces a decrease that is more
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important than the one observed with the irradiation alone.
These ﬁndings suggest that the effect of cisplatin combined
with irradiation is rather synergistic.
Biston et al. (2004) have hypothesized that the effects of the
PAT-Plat could be explained by the emission of Auger elec-
trons. When the platinum is irradiated above its K-edge
energy, an electron of the K-shell is extracted creating a
vacancy. This vacancy is ﬁlled by rearrangement of electrons
from the outer shells leading to an Auger effect. Auger elec-
trons interact at distances shorter than a few nanometers with
target (macro) molecules. The targets can be the DNA as
cisplatin binds to it. However, the most probable interaction
is with the water molecules. Secondary electrons (photoelec-
trons, Auger electrons) can generate important quantities of
reactive oxygen species (ROS) that can indirectly create DNA
damage. These direct and indirect pathways create DNA
single (SSB) and double (DSB) strand-breaks on tumor cells.
Moreover, adducts of cisplatin on DNA can inhibit repair
pathways after radiotherapy (Turchi et al., 2000). In that case,
the synergistic effect of the PAT-Plat is not only due to
photoelectric effects but may be partly explained by the
inhibition of DNA repair pathways.
4.2. Effects of the PAT-Plat on tumor vasculature
Effects of the PAT-Plat on the tumor vasculature in the
perfused rim of the gliomas were observed by means of
intravital two-photon microscopy. At day 5 post-treatment
(Fig. 2f) a decrease of the perfused vascular surface at the
periphery of the tumor was measured. These vessels are
mostly located at the surface of the subcutaneous gliomas.
These phenomena appeared largely before a regression of
central tumor volume, which started three weeks after
complete treatment.
We hypothesize that the whole treatment may induce
endothelial cell death, collapse of the angiogenic vessels,
thrombosis and consequently inhibition of tumor perfusion.
Note that after irradiation only, the tumor vessels were still
functional (Fig. 2d).
In summary, we propose a model showing that photo-
activation of cisplatin induces an effect on tumor cells medi-
ated by DNA damage caused by photoelectrons and reactive
oxygen species. More precisely, the irradiation and secondary
electrons generated by the photoactivation of the cisplatin
generate SSB and DSB on DNA that are less likely to be
repaired as the cisplatin can inhibit some repair pathways
(Turchi et al., 2000). Moreover, a second effect is observed on
proliferating vascular endothelial cells creating an inhibition
of the tumor blood perfusion (Fig. 4a). Comparable effects
were observed on microvascular endothelium cells in the
intestine after irradiation only (Paris et al., 2001). The latter
phenomenon had a larger impact on the hypoxic tumor
regions [see Figs. 4(b)–4(c)], which are less perfused than
those at the periphery of the tumor. Here, glioma cells were
close to the functional vasculature of the host muscle tissue,
where tumor recurrence appeared ﬁrst.
5. Conclusions
The whole PAT-Plat protocol showed a synergistic effect
between cisplatin and irradiation on the F98 glioma growth. In
accordance with the present observations and the previous
experiments using the PAT-Plat protocol (Biston et al., 2004;
Rousseau et al., 2007a), we hypothesize that the transient
tumor growth reduction is synergistic interactions of tumor-
cell-killing effects and reduction of the tumor blood perfusion.
This preclinical study has shown that changes in tumor blood
perfusion and consequently tumor volume are important
parameters in the prediction of the tumor response after the
PAT-Plat protocol.
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Figure 4
A hypothetical model explaining the effects of the PAT-Plat protocol. (a)
General model for PAT-Plat effects. Irradiation leads to cellular damages
such as DNA SSB and DSB directly or indirectly via the creation of
reactive oxygen species. These damages are less likely repaired thanks
to the inhibition of certain repair pathways by the cisplatin. Moreover,
the PAT-Plat reduces the perfused vascular surface. This reduction of
the perfusion can indirectly induce tumor cell death. (b) Schematic
representation of the regression observed on a F98 glioma one month
after the treatment. Grey area: part of the tumor that has disappeared
after the whole treatment. The black arrow indicates the tumor volume
reduction. (c) Macrophotograph of a F98 glioma one month after the
whole treatment. Note that the dark spots show the blood vessel
coagulations after the whole PAT-Plat treatment (white arrows).
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